Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Medtronic
Baxter
Moodys

Last Updated: May 25, 2022

QUARTETTE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Quartette, and what generic alternatives are available?

Quartette is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in thirteen countries.

The generic ingredient in QUARTETTE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

DrugPatentWatch® Generic Entry Outlook for Quartette

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Paragraph IV (Patent) Challenges for QUARTETTE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
QUARTETTE Tablets ethinyl estradiol; levonorgestrel 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg 204061 1 2013-07-10

US Patents and Regulatory Information for QUARTETTE

QUARTETTE is protected by two US patents.

Patents protecting QUARTETTE

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTION OF PREGNANCY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm QUARTETTE ethinyl estradiol; levonorgestrel TABLET;ORAL 204061-001 Mar 28, 2013 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Teva Branded Pharm QUARTETTE ethinyl estradiol; levonorgestrel TABLET;ORAL 204061-001 Mar 28, 2013 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for QUARTETTE

When does loss-of-exclusivity occur for QUARTETTE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1931
Estimated Expiration: See Plans and Pricing

Australia

Patent: 05294269
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0516247
Estimated Expiration: See Plans and Pricing

Patent: 0716291
Estimated Expiration: See Plans and Pricing

Canada

Patent: 82530
Estimated Expiration: See Plans and Pricing

Patent: 68211
Estimated Expiration: See Plans and Pricing

China

Patent: 1068552
Estimated Expiration: See Plans and Pricing

Patent: 1626760
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 14556
Estimated Expiration: See Plans and Pricing

Patent: 79461
Estimated Expiration: See Plans and Pricing

Patent: 92332
Estimated Expiration: See Plans and Pricing

Patent: 92333
Estimated Expiration: See Plans and Pricing

Israel

Patent: 2287
Estimated Expiration: See Plans and Pricing

Patent: 8441
Estimated Expiration: See Plans and Pricing

Japan

Patent: 08515909
Estimated Expiration: See Plans and Pricing

Patent: 10508275
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 07004120
Estimated Expiration: See Plans and Pricing

Patent: 09004616
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 09120528
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 090094437
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 0626161
Estimated Expiration: See Plans and Pricing

Patent: 0831107
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QUARTETTE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2392332 Procédé de traitement hormonal utilisant des régimes de cycle étendu à dose croissante (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens) See Plans and Pricing
Brazil PI0716291 MÉTODO DE CONTRACEPÇÃO E KITS FARMACÊUTICOS See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008127303 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for QUARTETTE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1214076 49/2008 Austria See Plans and Pricing PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521 122015000093 Germany See Plans and Pricing PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521 15C0050 France See Plans and Pricing PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Express Scripts
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.